HIV-1 proteins, Tat and gp120, target the developing dopamine system

Current HIV Research

Volumn 13, Issue 1, 2015, Pages 21-42

  Fitting, Sylvia ^a   Booze, Rosemarie M ^b   Mactutus, Charles F ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Development; Dopamine; Gp120; Neurocognitive impairment; Pediatric HIV AIDS; Tat

Indexed keywords

DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRANSACTIVATOR PROTEIN; TYROSINE 3 MONOOXYGENASE; ZIDOVUDINE; DOPAMINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL (TOPIC); DISEASE TRANSMISSION; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENCEPHALITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MESENCEPHALON; NERVOUS SYSTEM DEVELOPMENT; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); CENTRAL NERVOUS SYSTEM; CHILD; CHILD DEVELOPMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION; TRANSMISSION;

CENTRAL NERVOUS SYSTEM; CHILD; CHILD DEVELOPMENT; DOPAMINE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; SYNAPTIC TRANSMISSION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84930984538     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X13666150121110731     Document Type: Article

References (276)

1. UNAIDS: The Gap Report. 2014.
2. [2] Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and muscosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. The New England Journal of Medicine 1981; 305(24): 1425-31.
3. [3] Mildvan D, Mathur U, Enlow RW, et al. Opportunistic infections and immune deficiency in homosexual men. Annals of internal medicine 1982; 96(1 Pt 6): 700-4.
4. [4] Oleske JM, Minnefor A, Cooper R, et al. Immune deficiency syndrom in children. The Journal of the American Medical Association 1983; 249(17): 2345-9.
5. [5] Rubinstein A, Sicklick M, Gupta A, et al. Acquired immunodeficiency with reversed T4/T8 ratios in infants born to promiscuous and drug-addicted mothers. The Journal of the American Medical Association 1983; 249(17): 2350-6.
6. [6] Shaw GM, Harper ME, Hahn BH, et al. HTLV-III infection in brains of children and adults with AIDS encephalopathy. Sciene 1985; 227(4683): 177-82.
7. [7] Barnes DM: Brain Function Decline in Children with AIDS. Science 1986; 232(4755): 1196.
8. UNAIDS: The Gap Report. 2013.
9. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P: Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2007(1): CD003510.
10. [10] Chi BH, Bolton-Moore C, Holmes CB: Prevention of mother-tochild HIV transmission within the continuum of maternal, newborn, and child health services. Curr Opin HIV AIDS 2013; 8(5): 498-503.
11. [11] Kourtis AP, Bulterys M, Nesheim SR, Lee FK: Understanding the timing of HIV transmission from mother to infant. JAMA 2001; 285(6): 709-712.
12. [12] Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29(5): 484-94.
13. [13] Connor EM, Sperling RS, Gelber R, et al. Reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331(18): 1173-80.
14. [14] Nesheim S, Harris LF, Lampe M: Elimination of perinatal HIV infection in the USA and other high-income countries: achievements and challenges. Curr Opin HIV AIDS 2013; 8(5): 447-56.
15. [15] Okechukwu AA, Abdulrahaman IE: The impact of Prevention of mother to Child Transmission of HIV programme in the Federal Capital Territory, Abuja. Niger J Med 2008; 17(2): 191-7.
16. [16] Adair T: Unmet need for contraception among HIV-positive women in Lesotho and implications for mother-to-child transmission. J Biosoc Sci 2009; 41(2): 269-78.
17. [17] Viani RM, Ruiz-Calderon J, Lopez G, Chacon-Cruz E, Spector SA: Mother-to-child HIV transmission in a cohort of pregnant women diagnosed by rapid HIV testing at Tijuana General Hospital, Baja California, Mexico. J Int Assoc Physicians AIDS Care (Chic) 2010; 9(2): 82-6.
18. [18] Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22(8): 973-81.
19. [19] Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008; 22(2): 289-99.
20. [20] Purohit V, Rapaka RS, Shurtleff D: Mother-to-child transmission (MTCT) of HIV and drugs of abuse in post-highly active antiretroviral therapy (HAART) era. J Neuroimmune Pharmacol 2010; 5(4): 507-15.
21. [21] Purohit V, Rapaka RS, Schnur P, Shurtleff D: Potential impact of drugs of abuse on mother-to-child transmission (MTCT) of HIV in the era of highly active antiretroviral therapy (HAART). Life Sci 2011; 88(21-22): 909-16.
22. WHO: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Available: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html. 2013.
23. [23] Heidari S, Mofenson L, Cotton MF, Marlink R, Cahn P, Katabira E: Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr 2011; 57(4): 290-6.
24. Mofenson LM, Watts DH: Safety of pediatric HIV elimination: the growing population of HIV-and antiretroviral-exposed but uninfected infants. PLoS Med 2014; 11(4): e1001636.
25. Sibiude J, Mandelbrot L, Blanche S, et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med 2014; 11(4): e1001635.
26. [26] Chiappini E, Berti E, Gianesin K, et al. Pediatric human immunodeficiency virus infection and cancer in the highly active antiretroviral treatment (HAART) era. Cancer letters 2014; 347(1): 38-45.
27. [27] Gray L: Clinical and biological disease progression in vertically acquired paediatric HIV infection. Medycyna Wieku Rozwojowego 2003; 7(4 Pt 1): 437-48.
28. [28] Rouet F, Sakarovitch C, Msellati P, et al. Pediatric viral human immunodeficiency virus type 1 RNA levels, timing of infection, and disease progression in African HIV-1-infected children. Pediatrics 2003; 112(4): e289.
29. [29] Dunn D, Woodburn P, Duong T, et al. Study HIVPPMC, Concerted Action on Sero-Conversion to A, Death in Europe C: Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIVinfected children and adults. J Infect Dis 2008; 197(3): 398-404.
30. [30] Becquet R, Marston M, Dabis F, et al. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PLoS One 2012; 7(2): e28510.
31. [31] Hazra R, Siberry GK, Mofenson LM: Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annual review of medicine 2010; 61: 169-85.
32. Federal Interagency Forum on Childand Family Statistics. In: wwwchildstatsgov. accessed 10/2014.
33. [33] Belman AL, Diamond G, Dickson D, et al. Pediatric acquired immunodeficiency syndrome. American Journal of Diseases of Children 1988; 142: 29-35.
34. [34] Epstein LG, Sharer LR, Joshi V, et al. Progressive encephalopathy in children with acquired immune deficiency syndrome. Annals of Neurology 1985; 17(5): 488-96.
35. [35] Epstein LG, Sharer LR, Oleske JM, et al. Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics 1986; 78(4): 678-87.
36. [36] Sharer LR: Pathology of HIV-1 infection of the central nervous system. Journal of Neuropathology and Experimental Neurology 1992; 51(1): 3-11.
37. [37] Wiley CA, Belman AL, Dickson DW, Rubinstein A, Nelson JA: Human immunodeficiency virus within the brains of children with AIDS. Clinical Neuropathology 1990; 9(1): 1-6.
38. [38] Tardieu M, Le Chenadec J, Persoz A, et al. HIV-1-related encephalopathy in infants compared with children and adults. French Pediatric HIV Infection Study and the SEROCO Group. Neurology 2000; 54(5): 1089-1095.
39. [39] Stromme P, Kanavin OJ, Abdelnoor M, et al. Incidence rates of progressive childhood encephalopathy in Oslo, Norway: a population based study. BMC Pediatr 2007; 7: 25.
40. [40] Meeker RB, Boles JC, Bragg DC, Robertson K, Hall C: Development of neuronal sensitivity to toxins in cerebrospinal fluid from HIV-type 1-infected individuals. AIDS Res Hum Retroviruses 2004; 20(10): 1072-86.
41. [41] Belman AL: Infants, children, and adolescents. In: AIDS and the nervous system. Edited by Berger; JR, Levy RM, Second edn. Philadelphia: Lippincott-Raven; 1997: 223-53.
42. [43] Deeks SG, Lewin SR, Havlir DV: The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382(9903): 1525-33.
43. [44] Paramesparan Y, Garvey LJ, Ashby J, et al. High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1-infected adolescents surviving to adulthood. J Acquir Immune Defic Syndr 2010; 55(1): 134-6.
44. [45] Burns S, Hernandez-Reif M, Jessee P: A review of pediatric HIV effects on neurocognitive development. Issues in comprehensive pediatric nursing 2008; 31(3): 107-21.
45. [46] Mintz M: Clinical comparison of adult and pediatric NeuroAIDS. Advances in Neuroimmunology 1994; 4: 207-221.
46. [47] Mintz M: Neurological findings in pediatric HIV/AIDS. Clinical features. In: The Neurology of AIDS. Edited by E GH, Igor G, Paul EI, A LS, Susan S, Second Edition edn. Oxford: University Press; 2005: 639-58.
47. [48] Tobin NH, Aldrovandi GM: Immunology of pediatric HIV infection. Immunological reviews 2013; 254(1): 143-69.
48. [49] Gelbard HA, Epstein LG: HIV-1 encephalopathy in children. Current Opinion in Neurobiology 1995; 7(6): 655-62.
49. [50] Le Doare K, Bland R, Newell ML: Neurodevelopment in children born to HIV-infected mothers by infection and treatment status. Pediatrics 2012; 130(5): e1326-44.
50. [51] Webb KM, Mactutus CF, Booze RM: The ART of HIV therapies: dopaminergic deficits and future treatments for HIV pediatric encephalopathy. Expert Rev Anti Infect Ther 2009; 7(2): 193-203.
51. [52] Lodha R, Manglani M: Antiretroviral therapy in children: recent advances. Indian journal of pediatrics 2012; 79(12): 1625-33.
52. [53] Rakhmanina N, Phelps BR: Pharmacotherapy of pediatric HIV infection. Pediatric clinics of North America 2012; 59(5): 1093-115.
53. [54] Cadilla A, Qureshi N, Johnson DC: Pediatric antiretroviral therapy. Expert Rev Anti Infect Ther 2010; 8(12): 1381-1402.
54. [55] Wiley CA, Nelson JA: Human immunodeficiency virus: Infection of the nervous system. Current Topics in Microbiology and Immunology 1990; 160: 157-72.
55. [56] Belman AL, Lantos G, Horoupian D, et al. AIDS: Calcification of the basal ganglia in infants and children. Neurology 1986; 36: 1192-9.
56. [57] Epstein LG, Sharer LR, Goudsmit J: Neurological and neuropathological features of human immonudeficiency virus infection in children. Annals of Neurology 1988; 23(Suppl): S19-S23.
57. [58] Fowler MG: Pediatric HIV infection: neurologic and neuropsychologic findings. Acta PaediatricsSupplementum 1994; 400: 59-62.
58. [59] Price RW, Brew B, Sidtis J, et al. The brain in AIDS: Central nervous system HIV-1 infection and AIDS dementia complex. Science 1988; 239(4840): 586-92.
59. [60] Llorente AM, Brouwers P, Leighty R, et al. An analysis of select emerging executive skills in perinatally HIV-1-infected children. Applied neuropsychology Child 2014; 3(1): 10-25.
60. [61] Nieoullon A: Dopamine and the regulation of cognition and attention. Progress in Neurobiology 2002; 67(1): 53-83.
61. [62] Mintz M, Hoyt L, McSherry G, Mendelson J, Oleske J: Levodopa therapy improves motor function in HIV-infected children with extrapramidal syndromes. Neurology 1996; 47(6): 1583-5.
62. [63] Berger JR, Arendt G: HIV dementia: the role of the basal ganglia and dopaminergic systems. Journal of Psychopharmacology 2000; 14(3): 214-21.
63. [64] Brew BJ, Rosenblum M, Price Richard W: AIDS dementia complex and primary HIV brain infection. Journal of Neuroimmunology 1988; 20: 133-140.
64. [65] Nath A, Anderson C, Jones M, et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. Journal of Psychopharmacology 2000; 14(3): 222-2.
65. [66] Berger JR, Nath A: HIV dementia and the basal ganglia. Intervirology 1997; 40: 122-131.
66. [67] Arendt G, von Giesen HJ: Human immunodeficiency virus dementia: evidence of a subcortical process from studies of fine finger movements. Journal of Neurovirology 2002; 8(Suppl 2): 27-32.
67. [68] Sardar AM, Czudek C, Reynolds GP: Dopamine deficits in the brain: the neurochemical basis of parkinsonian smptoms in AIDS. NeuroReport 1996; 7: 910-2.
68. [69] von Giesen HJ, Wittsack HJ, Wenserski F, et al. Basal ganglia metabolic abnormalities in minor motor disorders associated with human immunodeficiency virus type 1. Archives of Neurology 2001; 58: 1281-6.
69. [70] Navia BA, Cho ES, Petito CK, Price RW: The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986; 19(6): 525-35.
70. [71] Arendt G, Hefter H, Elsing C, Strohmeyer G, Freund HJ: Motor dysfunction in HIV-infected patients without clinically detectable central-nervous deficit. Journal of neurology 1990; 237(6): 362-8.
71. [72] Berger JR, Arendt G: HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol 2000; 14(3): 214-21.
72. [73] Berger JR, Kumar M, Kumar A, Fernandez JB, Levin B: Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 1994; 8(1): 67-71.
73. [74] Hriso E, Kuhn T, Masdeu JC, Grundman M: Extrapramidal smptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. The American Journal of Psychiatry 1991; 148: 1558-61.
74. [75] Mirsattari SM, Power C, Nath A: Parkinsonism with HIV infection. Mov Disord 1998; 13(4): 684-9.
75. [76] Hollander H, Golden J, Mendelson T, Cortland D: Extrapyramidal symptoms in AIDS patients given low-dose metoclopramide or chlorpromazine. Lancet 1985; 2(8465): 1186.
76. [77] di Rocco A, Bottiglieri T, Dorfman D, et al. Decreased homovanilic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1-infected patients. Clinical Neuropharmacology 2000; 23(4): 190-4.
77. [78] Larsson M, Hagberg L, Forsman A, Norkrans G: Cerebrospinal fluid catecholamine metabolites in HIV-infected patients. J Neurosci Res 1991; 28(3): 406-9.
78. [79] Obermann M, Kuper M, Kastrup O, et al. Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV. Journal of neurology 2009; 256(6): 948-53.
79. Silvers JM, Aksenova MV, Aksenov MY, Mactutus CF, Booze RM: Neurotoxicity of HIV-1 Tat protein in primary cultures of rat midbrain neurons. Possible role for D1 dopamine receptors. In.; 2006.
80. [81] Kumar AM, Fernandez JB, Singer EJ, et al. Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol 2009; 15(3): 257-74.
81. [82] Kumar AM, Ownby RL, Waldrop-Valverde D, Fernandez B, Kumar M: Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J Neurovirol 2011; 17(1): 26-40.
82. [83] Meade CS, Conn NA, Skalski LM, Safren SA: Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence. Journal of behavioral medicine 2011; 34(2): 128-38.
83. [84] Aylward EH, Brettschneider PD, McArthur JC, et al. Magnetic resonance imaging measurement of gray matter volume reductions in HIV dementia. Am J Psychiatry 1995; 152(7): 987-94.
84. [85] Aylward EH, Henderer JD, McArthur JC, et al. Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 1993; 43(10): 2099-104.
85. [86] Tracey I, Carr CA, Guimaraes AR, et al. Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: A proton magnetic resonance spectroscopic study. Neurology 1996; 46(3): 783-8.
86. [87] Tracey I, Hamberg LM, Guimaraes AR, et al. Increased cerebral blood volume in HIV-positive patients detected by functional MRI. Neurology 1998; 50(6): 1821-6.
87. [88] Wang GJ, Chang L, Volkow ND, et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 2004; 127: 2452-8.
88. [89] Chang L, Wang GJ, Volkow ND, et al. Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. NeuroImage 2008; 42(2): 869-78.
89. [90] Chudasama Y, Robbins TW: Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans. Biological psychology 2006; 73(1): 19-38.
90. [91] Aksenov MY, Aksenova MV, Silvers JM, Mactutus CF, Booze RM: Different effects of selective dopamine uptake inhibitors, GBR 12909 and WIN 35428; on HIV-1 Tat toxicity in rat fetal midbrain neurons. Neurotoxicology 2008; 29(6): 971-7.
91. [92] Zhu J, Mactutus CF, Wallace DR, Booze RM: HIV-1 Tat proteininduced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes. J Pharmacol Exp Ther 2009; 329(3): 1071-83.
92. [93] Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM: Hyperdopaminergic tone in HIV-1 protein treated rats and cocaine sensitization. J Neurochem 2010; 115(4): 885-96.
93. [94] Zhu J, Ananthan S, Mactutus CF, Booze RM: Recombinant human immunodeficiency virus-1 transactivator of transcription1-86 allosterically modulates dopamine transporter activity. Synapse 2011; 65(11): 1251-4.
94. [95] Midde NM, Gomez AM, Zhu J: HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes. J Neuroimmune Pharmacol 2012; 7(3): 629-39.
95. [96] Midde NM, Huang X, Gomez AM, et al. Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine transport and transporter conformational transitions. J Neuroimmune Pharmacol 2013; 8(4): 975-87.
96. [97] Perry SW, Barbieri J, Tong N, et al. Gelbard HA: Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax. J Neurosci 2010; 30(42): 14153-64.
97. [98] Aksenov MY, Aksenova MV, Nath A, Ray PD, Mactutus CF, Booze RM: Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: The role of oxidative stress and D1 dopamine receptor. Neurotoxicology 2006; 27(2): 217-28.
98. [99] Langford D, Adame A, Grigorian A, et al. Patterns of selective neuronal damage in methamphetamine-user AUDS patients. Journal of Acquired Immune Deficiency Syndrome 2003; 34(467): 474.
99. [100] Goodkin K, Shapshak P, Metsch LR, et al. Cocaine abuse and HIV-1 infection: Epidemiology and neuropathogenesis. Journal of Neuroimmunology 1998; 83: 88-101.
100. [101] Jernigan TL, Gamst AC, Archibald SL, et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. American Journal of Psychiatry 2005; 162(8): 1461-72.
101. [102] Theodore S, Cass WA, Maragos WF: Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum. Neuroscience 2006; 137: 925-35.
102. [103] Nath A, Hauser KF, Wojna V, et al. Molecular basis for interactions of HIV and drugs of abuse. Journal of Acquired Immune Deficiency Syndrome 2002; 31: S62-S69.
103. [104] Maragos WF, Young KL, Turchan JT, et al. Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. Journal of Neurochemistry 2002; 83: 955-63.
104. [105] Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM: The human immunodeficiency virus-1-associated protein, Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study. Neuroscience 2009; 159(4): 1292-9.
105. [106] Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM: In vivo microdialysis in awake, freely moving rats demonstrates HIV-1 Tat-induced alterations in dopamine transmission. Synapse 2009; 63(3): 181-5.
106. [107] Ferris MJ, Mactutus CF, Booze RM: Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev 2008; 32(5): 883-909.
107. [108] Moran LM, Aksenov MY, Booze RM, Webb KM, Mactutus CF: Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge. Curr HIV Res 2012; 10(5): 415-24.
108. [109] Moran LM, Booze RM, Webb KM, Mactutus CF: Neurobehavioral alterations in HIV-1 transgenic rats: evidence for dopaminergic dysfunction. Exp Neurol 2013; 239: 139-47.
109. [110] Davies J, Everall IP, Weich S, et al. HIV-associated brain pathology in the United Kingdom: an epidemiological study. AIDS 1997; 11(9): 1145-50.
110. [111] Bjorklund A, Lindvall O: Dopamine-containing systems in the CNS. In: Handbook of Chemical Neuroatomy Vol2: Classical Transmitters in the CNS, Part I. Edited by Bjorklund A, Hokfelt T: Elsevier Science Publishers B.V.; 1984: 55-122.
111. [112] Aksenova MV, Silvers JM, Aksenov MY, et al. HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: Changes in dopamine transporter binding and immunoreactivity. Neuroscience Letters 2006; 395(3): 235-9.
112. [113] Robertson KR, Parsons TD, Sidtis JJ, et al. Timed Gait test: normative data for the assessment of the AIDS dementia complex. Journal of clinical and experimental neuropsychology 2006; 28(7): 1053-64.
113. [114] Sullivan EV, Rosenbloom MJ, Rohlfing T, et al. Pontocerebellar contribution to postural instability and psychomotor slowing in HIV infection without dementia. Brain imaging and behavior 2011; 5(1): 12-24.
114. [115] Valcour V, Watters MR, Williams AE, Sacktor N, McMurtray A, Shikuma C: Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy. J Neurovirol 2008; 14(5): 362-7.
115. [116] Kieburtz KD, Epstein LG, Gelbard HA, Greenamyre JT: Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. Archives of Neurology 1991; 48(12): 1281-4.
116. [117] Martin LJ: Neuronal cell death in nervous system development, disease, and injury (Review). International Journal of Molecular Medicine 2001; 7(5): 455-78.
117. [118] Wallen A, Perlmann T: Transcriptional control of dopamine neuron development. Ann N Y Acad Sci 2003; 991: 48-60.
118. [119] Cooper JR, Bloom FE, Roth RHTBBoNOUP, NY, 7th ed: The Biochemical Basis of Neuropharmacology, 7th ed edn. New York: Oxford University Press; 1996.
119. [120] Vallone D, Picetti R, Borrelli E: The involvement of dopamine in various physiological functions: From drug addiction to cell proliferation. In: Development of dopaminergic neurons. Edited by Umberto dP, Roberto P-A, Carla P-C; 1999: 101-22.
120. [121] Carlsson A: Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. Journal of Neural Transmission 2002; 109: 777-87.
121. [122] Ouchi Y, Kanno T, Okada H, et al. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease. Brain 2001; 124(Pt 4): 784-92.
122. [123] Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Riederer P: Parkinsonism in HIV dementia. J Neural Transm 2002; 109(5-6): 767-75.
123. [124] Perrone-Capano C, Pernas-Alonso R, di Porzio U: Development of midbrain dopaminergic neurons. In: Development of dopaminergic neurons. Edited by Umberto dP, Roberto P-A, Carla P-C; 1999: 37-55.
124. [125] Harrod SB, Mactutus CF, Fitting S, Hasselrot U, Booze RM: Intraaccumbal Tat1-72 alters acute and sensitized responses to cocaine. Pharmacol Biochem Behav 2008; 90(4): 723-9.
125. [126] Berger B, Gaspar P, Verney C: Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci 1991; 14(1): 21-7.
126. [127] Goldman-Rakic PS: The cortical dopamine system: role in memory and cognition. Advances in pharmacology 1998; 42: 707-11.
127. [128] Masliah E, Achim CL, Ge N, DeTeresa R, Terry RD, Wiley CA: Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol 1992; 32(3): 321-9.
128. [129] Masliah E, Heaton RK, Marcotte TD, et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol 1997; 42(6): 963-72.
129. [130] Burke RE: Postnatal developmental programmed cell death in dopamine neurons. Ann N Y Acad Sci 2003; 991: 69-79.
130. [131] Noisin EL, Thomas WE: Ontogeny of dopaminergic function in the rat midbrain tegmentum, corpus striatum and frontal cortex. Brain Res 1988; 469(1-2): 241-52.
131. [132] Dobbing J, Sands J: Comparative aspects of the brain growth spurt. Early Hum Dev 1979; 3(1): 79-83.
132. [133] Cooper ER, Nugent RP, Diaz C, et al. After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group. J Infect Dis 1996; 174(6): 1207-11.
133. [134] Specht LA, Pickel VM, Joh TH, Reis DJ: Light-microscopic immunocytochemical localization of tyrosine hydroxylase in prenatal rat brain. I. Early ontogeny. J Comp Neurol 1981; 199(2): 233-53.
134. [135] Pickel VM, Specht LA, Sumal KK, Joh TH, Reis DJ, Hervonen A: Immunocytochemical localization of tyrosine hydroxylase in the human fetal nervous system. J Comp Neurol 1980; 194(2): 465-74.
135. [136] Specht LA, Pickel VM, Joh TH, Reis DJ: Light-microscopic immunocytochemical localization of tyrosine hydroxylase in prenatal rat brain. II. Late ontogeny. J Comp Neurol 1981; 199(2): 255-76.
136. [137] Reyes MG, Faraldi K, Senseng CS, Flowers C, Fariello R: Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathologica 1991; 82: 39-44.
137. [138] Itoh K, Mehraein P, Weis S: Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol 2000; 99(4): 376-84.
138. [139] Antonopoulos J, Dori I, Dinopoulos A, Chiotelli M, Parnavelas JG: Postnatal development of the dopaminergic system of the striatum in the rat. Neuroscience 2002; 110(2): 245-56.
139. [140] Jung AB, Bennett JP.: Development of striatal dopaminergic function. I. Pre-and postnatal development of mRNAs and binding sites for striatal D1 (D1a) and D2 (D2a) receptors. Brain Res Dev Brain Res 1996; 94(2): 109-20.
140. [141] Shults CW, Hashimoto R, Brady RM, Gage FH: Dopaminergic cells align along radial glia in the developing mesencephalon of the rat. Neuroscience 1990; 38(2): 427-36.
141. [142] Olney JW: New insights and new issues in developmental neurotoxicology. Neurotoxicology 2002; 23(6): 659-68.
142. [143] Kalsbeek A, Voorn P, Buijs RM, Pool CW, Ulings HBM: Development of the dopaminergic innervation in the prefrontal cortex of the rat. The Journal of Comparative Neurology 1988; 269(58): 72.
143. [144] Damier P, Hirsch EC, Agid Y, Graybiel AM: The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999; 122 (Pt 8): 1421-36.
144. [145] Chen N, Reith ME: Structure and function of the dopamine transporter. Eur J Pharmacol 2000; 405(1-3): 329-39.
145. [146] Jones MV, Bell JE, Nath A: Immunolocalization of HIV envelope gp120 in HIV encephalitis with dementia. AIDS 2000; 14(17): 2709-13.
146. [147] Rho JM, Storey TW: Molecular ontogeny of major neurotransmitter receptor systems in the mammalian central nervous system: Norepinephrine, dopamine, serotonin, acetylcholine, and glycine. Journal of Child Neurology 2001; 16: 271-81.
147. [148] Volkow ND, Fowler JS, Gatley SJ, et al. PET evaluation of the dopamine system of the human brain. Journal of Nuclear Medicine 1996; 37(7): 1242-56.
148. [149] Booze RM, Wallace DR: Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: use of 7-OH-DPAT and [125I]-iodosulpride. Synapse 1995; 19(1): 1-13.
149. [150] Wallace DR, Booze RM: Identification of D3 and sigma receptors in the rat striatum and nucleus accumbens using (+/-)-7-hydroxy-N,N-di-n-[3H]propyl-2-aminotetralin and carbetapentane. J Neurochem 1995; 64(2): 700-710.
150. [151] Thomas WS, Neal-Beliveau BS, Joyce JN: There is a limited critical period for dopamine's effects on D1 receptor expression in the developing rat neostriatum. Brain Res Dev Brain Res 1998; 111(1): 99-106.
151. [152] Gao J, Gross J, Andeeva N, et al. Hypoxia induces differential changes of dopamine metabolism in mature and immature mesencephalic and diencephalic cell cutures. Journal of Neural Transmission 1999; 106: 111-22.
152. [153] Westendorp MO, Frank R, Ochsenbauer C, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375(6531): 497-500.
153. [154] Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48(3): 350-61.
154. [155] Tan R, Westfall AO, Willig JH, et al. Clinical outcome of HIVinfected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47(5): 553-8.
155. [156] Willen EJ: Neurocognitive outcomes in pediatric HIV. Ment Retard Dev Disabil Res Rev 2006; 12(3): 223-8.
156. [157] Webb KM, Aksenov MY, Mactutus CF, Booze RM: Evidence for developmental dopaminergic alterations in the human immunodeficiency virus-1 transgenic rat. J Neurovirol 2010; 16(2): 168-73.
157. [158] Moran LM, Booze RM, Mactutus CF: Time and time again: temporal processing demands implicate perceptual and gating deficits in the HIV-1 transgenic rat. J Neuroimmune Pharmacol 2013; 8(4): 988-97.
158. [159] Roscoe RF, Mactutus CF, Booze RM: HIV-1 Transgenic Female Rat: Synaptodendritic Alterations of Medium Spiny Neurons in the Nucleus Accumbens. J Neuroimmune Pharmacol 2014.
159. [160] Reid W, Sadowska M, Denaro F, et al. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A 2001; 98(16): 9271-76.
160. [161] Moran LM, Booze RM, Mactutus CF: Modeling deficits in attention, inhibition, and flexibility in HAND. J Neuroimmune Pharmacol 2014; 9(4): 508-21.
161. [162] Peng J, Vigorito M, Liu X, Zhou D, Wu X, Chang SL: The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART. J Neuroimmunol 2010; 218(1-2): 94-101.
162. [163] Lee DE, Reid WC, Ibrahim WG, et al. Imaging Dopaminergic Dysfunction as a Surrogate Marker of Neuropathology in a Small-Animal Model of HIV. Molecular imaging 2014; 13(0): 1-10.
163. [164] Bruce-Keller AJ, Chauhan A, Dimauga FO, et al. Synaptic transport of human immunodeficiency virus Tat protein causes neurotoxicity and gliosis in rat brain. The Journal of Neuroscience 2003; 23(23): 8417-22.
164. [165] Wallace DR, Dodson S, Nath A, Booze RM: Estrogene attenuates gp120-and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 2006; 59: 51-60.
165. [166] Zauli G, Secchiero P, Rodella L, et al. HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. The Journal of Biological Chemistry 2000; 275(6): 4159-65.
166. [167] Cass WA, Harned ME, Peters LE, Nath A, Maragos WF: HIV-1 protein Tat potentiation of methamphetamine-induced decrease in evoked overflow of dopamine in the striatum of the rat. Brain Research 2003; 984(1-2): 133-42.
167. [168] Wallace DR: Overview of molecular, cellular, and genetic neurotoxicology. Neurology & clinical neurophysiology 2005; 23: 307-20.
168. [169] Aksenova MV, Aksenov MY, Mactutus CF, Booze RM: Cell culture models of oxidative stress and injury in the central nervous system. Current Neurovascular Research 2005; 2(1): 73-89.
169. [170] Dewar KM, Reader TA: Specific [3H]SCH23390 binding to D1 receptors in cerebral cortex and neostriatum: role of disulfide and sulfhydryl groups. Journal of Neurochemistry 1989; 52(472): 482.
170. [171] Kimura K, Sidhu A: Ascorbic acid inhibits 1251-SCH 23982 binding but increases the affinity of dopamine for D1 dopamine receptors. Journal of Neurochemistry 1994; 63: 2093-8.
171. [172] Koutsilieri E, Sopper S, Scheller S, ter Meulen V, Riederer P: Involvement of dopamine in the progression of AIDS dementia complex. Journal of Neural Transmission 2002; 109: 399-410.
172. [173] Fitting S, Booze RM, Hasselrot U, Mactutus CF: Dose-dependent long-term effects of Tat in the rat hippocampal formation: a designbased stereological study. Hippocampus 2010; 20(4): 469-80.
173. [174] Fitting S, Booze RM, Hasselrot U, Mactutus CF: Differential longterm neurotoxicity of HIV-1 proteins in the rat hippocampal formation: a design-based stereological study. Hippocampus 2008; 18(2): 135-47.
174. [175] Fitting S, Booze RM, Mactutus CF: Neonatal intrahippocampal injection of the HIV-1 proteins gp120 and Tat: differential effects on behavior and the relationship to stereological hippocampal measures. Brain Res 2008; 1232: 139-54.
175. [176] Petito CK, Roberts B, Cantando JD, Rabinstein A, Duncan R: Hippocampal injury and alterations in neuronal chemokine coreceptor expression in patients with AIDS. J Neuropathol Exp Neurol 2001; 60(4): 377-85.
176. [177] Barczyk M, Carracedo S, Gullberg D: Integrins. Cell and tissue research 2010; 339(1): 269-80.
177. [178] Kaul M, Lipton SA: Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 1999; 96(14): 8212-6.
178. [179] Meucci O, Fatatis A, Simen AA, et al. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci U S A 1998; 95(24): 14500-14505.
179. [180] Scorziello A, Florio T, Bajetto A, Thellung S, Schettini G: TGFbeta1 prevents gp120-induced impairment of Ca2+ homeostasis and rescues cortical neurons from apoptotic death. J Neurosci Res 1997; 49(5): 600-7.
180. [181] Nosheny RL, Mocchetti I, Bachis A: Brain-derived neurotrophic factor as a prototype neuroprotective factor against HIV-1-associated neuronal degeneration. Neurotox Res 2005; 8(1-2): 187-98.
181. [182] Bachis A, Major EO, Mocchetti I: Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization. J Neurosci 2003; 23(13): 5715-22.
182. [183] Melli G, Keswani SC, Fischer A, Chen W, Hoke A: Spatially distinct and functionally independent mechanisms of axonal degeneration in a model of HIV-associated sensory neuropathy. Brain 2006; 129(Pt 5): 1330-8.
183. [184] Bennett BA, Rusyniak DE, Hollingsworth CK: HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures. Brain Research 1995; 705: 168-76.
184. [185] Mocchetti I, Nosheny RL, Tanda G, Ren K, Meyer EM: Brainderived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system. Ann N Y Acad Sci 2007; 1122: 144-54.
185. [186] Bachis A, Aden SA, Nosheny RL, Andrews PM, Mocchetti I: Axonal transport of human immunodeficiency virus type 1 envelope protein glycoprotein 120 is found in association with neuronal apoptosis. J Neurosci 2006; 26(25): 6771-80.
186. [187] Mattson MP, Haughey NJ, Nath A: Cell death in HIV dementia. Cell Death and Differentiation 2005; 12(893): 904.
187. [188] Paquet M, Tremblay M, Soghomonian JJ, Smith Y: AMPA and NMDA glutamate receptor subunits in midbrain dopaminergic neurons in the squirrel monkey: an immunohistochemical and in situ hybridization study. The Journal of Neuroscience 1997; 17: 1377-96.
188. [189] Schmidt U, Beyer C, Oestereicher AB, et al. Activation of dopaminergic D1 receptors promotes morphogenesis of developing striatal neurons. Neuroscience 1996; 74(2): 453-60.
189. [190] Iskander S, Walsh KA, Hammond RR: Human CNS cultures exposed to HIV-1 gp120 reproduce dendritic injuries of HIV-1-associated dementia. Journal of Neroinflammation 2004; 1: 7.
190. [191] Brenneman DE, Westbrook GL, Fitzgerald SP, et al. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 1988; 335: 639-42.
191. [192] Fitting S, Booze RM, Mactutus CF: Neonatal intrahippocampal glycoprotein 120 injection: The role of dopaminergic alterations in prepulse inhibition in adult rats. The Journal of Pharmacology and Experimental Therapeutics 2006; 318(3): 1352-8.
192. [193] Braff DL, Stone C, Callaway E, Geyer MA, Glick ID, Bali L: Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978; 15: 339-43.
193. [194] Fein G, Biggins CA, MacKay S: Delayed latency of the eventrelated brain potential P3A component in HIV disease. Progressive effects with increasing cognitive impairment. Archives of Neurology 1995; 52: 1109-18.
194. [195] Donahoe RM, Vlahov D: Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol 1998; 83(1-2): 77-87.
195. Fitting S, Booze RM, Mactutus CF: Neonatal intrahippocampal gp120 injection: An examination early in development. Neurotoxicology 2006; 31 ([Epub ahead of print]).
196. [197] Shoemaker JM, Saint MRL, Bongiovanni MJ, et al. Prefrontal D1 and ventral hippocampal N-methyl-D-aspartate regulation of startle gating in rats. Neuroscience 2005; 135(385): 394.
197. [198] Scarlatti G: Mother-to-child transmission of HIV-1: advances and controversies of the twentieth centuries. AIDS Reviews 2004; 6(2): 67-78.
198. [199] Capparelli E, Rakhmanina N, Mirochnick M: Pharmacotherapy of perinatal HIV. Seminars in Fetal & Neonatal Medicine 2005; 10(2): 161-75.
199. [200] Brenner BG, Wainberg MA: The role of antiretrovirals and drug resistance in vertical transmission of HIV-1 infection. Annals of the New York Academy of Sciences 2000; 918: 9-15.
200. [201] Avramis VI, Kwock R, Solorzano MM, Gomperts E: Evidence of in vitro development of drug resistance to azidothymidine in Tlymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 1993; 6(12): 1287-96.
201. [202] Equils O, Garratty E, Wei LS, et al. Recovery of replicationcompetent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy. The Journal of Infectious Diseases 2000; 182(3): 751-7.
202. [203] Martin SC, Wolters PL, Toledo-Tamula MA, et al. Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART). Dev Neuropsychol 2006; 30(2): 633-57.
203. [204] Saksena NK, Smit TK: HAART & the molecular biology of AIDS dementia complex. The Indian Journal of Medical Research 2005; 121: 256-69.
204. [205] Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17(1): 3-16.
205. [206] Schapira AH: Present and future APO drug gp120 treatment for Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry 2005; 76: 1472-8.
206. [207] Czub S, Czub M, Koutsilieri E, Sopper S, Villinger F, Muller JG, Stahl-Hennig C, Riederer P, ter Meulen V, Gosztonyi G: Modulation of simian immunodeficiency virus neuropathology by dopaminergic APO drugs. Acta Neuropathologica 2004; 107: 216-26.
207. [208] Rohr O, Sawaya BE, Lecestre D, Aunis D, Schaeffer E: Dopamine stimulates expression of the human immunodeficiency virus type 1 via NF-kappaB in cells of the immune system. Nucleic Acids Research 1999; 27(16): 3291-9.
208. [209] Scheller C, Sopper S, Jassoy C, ter Meulen V, Riederer P, Koutsilieri E: Dopamine activates HIV in chronically infected T lymphoblasts. Journal of Neural Transmission 2000; 107(12): 1483-1489.
209. [210] Mollace V, Nottet HSLM, Clayette P, et al. Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends in Neuroscience 2001; 24(7): 411-6.
210. [211] Schwarz KB: Oxidative stress during viral infection: a review. Free Radical Biology & Medicine 1996; 21(5): 641-9.
211. [212] Pocernich CB, Sultana R, Mohmmad-Abdul H, Nath A, Butterfield DA: HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Research Reviews 2005; 50: 14-26.
212. [213] Aksenov MY, Hasselrot U, Wu G, et al. Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Research 2003; 987: 1-9.
213. Agrawal L, Louboutin JP, Reyes BA, van Bockstaele EJ, Strayer DS: Antioxidant enzyme gene delivery to protect from HIV-1 gp120-induced neuronal apoptosis. Gene Therapy 2006; Jul 27 (Epub ahead of print).
214. [215] Adams SM, Aksenova MV, Aksenov MY, Mactutus CF, Booze RM: ER-beta mediates 17beta-estradiol attenuation of HIV-1 Tatinduced apoptotic signaling. Synapse 2010; 64(11): 829-38.
215. [216] Corasaniti MT, Amantea D, Russo R, et al. 17b-Estradiol reduces neuronal apoptosis induced by HIV-1 gp120 in the neocortex of rat. Neurotoxicology 2005; 26: 893-903.
216. [217] Howard SA, Brooke AM, Sapolsky RM: Mechanisms of estrogenic protection against gp120-induced neurotoxicity. Experimental Neurology 2001; 168: 385-91.
217. [218] Russo R, Navarra M, Maiuolo J, et al. 17b-Estradiol protects SHSY5Y cells against HIV-1 gp120-induced cell death: Evidence for a role of estrogen receptors. Neurotoxicology 2005; 26: 905-13.
218. [219] Bertrand SJ, Aksenova MV, Mactutus CF, Booze RM: HIV-1 Tat protein variants: critical role for the cysteine region in synaptodendritic injury. Exp Neurol 2013; 248: 228-35.
219. [220] Bertrand SJ, Mactutus CF, Aksenova MV, Espensen-Sturges TD, Booze RM: Synaptodendritic recovery following HIV Tat exposure: neurorestoration by phytoestrogens. J Neurochem 2014; 128(1): 140-51.
220. [221] Fitting S, Ignatowska-Jankowska BM, Bull C, et al. Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. Biol Psychiatry 2013; 73(5): 443-53.
221. [222] Fitting S, Xu R, Bull C, et al. Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 2010; 177(3): 1397-410.
222. [223] Gorantla S, Poluektova L, Gendelman HE: Rodent models for HIV-associated neurocognitive disorders. Trends Neurosci 2012; 35(3): 197-208.
223. [224] Toggas SM, Masliah E, Rockenstein EM, et al. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994; 367(6459): 188-93.
224. [225] Ellis R, Langford D, Masliah E: HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007; 8(1): 33-44.
225. [226] Gould E, Woolley CS, Frankfurt M, McEwen BS: Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci 1990; 10(4): 1286-91.
226. [227] Woolley CS, McEwen BS: Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci 1992; 12(7): 2549-54.
227. [228] Sanchez AM, Flamini MI, Fu XD, et al. Rapid signaling of estrogen to WAVE1 and moesin controls neuronal spine formation via the actin cytoskeleton. Mol Endocrinol 2009; 23(8): 1193-202.
228. [229] Glazier MG, Bowman MA: A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Archives of internal medicine 2001; 161(9): 1161-72.
229. [230] Lephart ED, Setchell KD, Lund TD: Phytoestrogens: hormonal action and brain plasticity. Brain Res Bull 2005; 65(3): 193-8.
230. [231] Desplats P, Dumaop W, Smith D, et al. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology 2013; 80(15): 1415-23.
231. [232] Kim HJ, Martemyanov KA, Thayer SA: Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. J Neurosci 2008; 28(48): 12604-13.
232. [233] Shin AH, Kim HJ, Thayer SA: Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat. Br J Pharmacol 2012; 166(3): 1002-17.
233. [234] Kramar EA, Chen LY, Brandon NJ, et al. Cytoskeletal changes underlie estrogen's acute effects on synaptic transmission and plasticity. J Neurosci 2009; 29(41): 12982-93.
234. [235] Liu F, Day M, Muniz LC, et al. Activation of estrogen receptorbeta regulates hippocampal synaptic plasticity and improves memory. Nat Neurosci 2008; 11(3): 334-43.
235. [236] Srivastava DP, Woolfrey KM, Liu F, Brandon NJ, Penzes P: Estrogen receptor ss activity modulates synaptic signaling and structure. J Neurosci 2010; 30(40): 13454-60.
236. [237] Phan A, Lancaster KE, Armstrong JN, MacLusky NJ, Choleris E: Rapid effects of estrogen receptor alpha and beta selective agonists on learning and dendritic spines in female mice. Endocrinology 2011; 152(4): 1492-502.
237. [238] Sharer LR: Pathology of HIV-1 infection of the central nervous system. A review. J Neuropathol Exp Neurol 1992; 51(1): 3-11.
238. [239] Mintz M: Clinical comparison of adult and pediatric NeuroAIDS. Adv Neuroimmunol 1994; 4(3): 207-21.
239. [240] States LJ, Zimmerman RA, Rutstein RM: Imaging of pediatric central nervous system HIV infection. Neuroimaging Clin N Am 1997; 7(2): 321-39.
240. [241] Shanbhag MC, Rutstein RM, Zaoutis T, et al. Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy. Arch Pediatr Adolesc Med 2005; 159(7): 651-6.
241. [242] Van Rie A, Harrington PR, Dow A, Robertson K: Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: a global perspective. Eur J Paediatr Neurol 2007; 11(1): 1-9.
242. [243] Epstein LG, Sharer LR, Oleske JM, et al. Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics 1986; 78(4): 678-87.
243. [244] Belman AL, Diamond G, Dickson D, et al. Pediatric acquired immunodeficiency syndrome. Neurologic syndromes. Am J Dis Child 1988; 142(1): 29-35.
244. [245] Brouwers P, Tudor-Williams G, DeCarli C, et al. Relation between stage of disease and neurobehavioral measures in children with symptomatic HIV disease. AIDS 1995; 9(7): 713-20.
245. [246] Sharer LR, Epstein LG, Cho ES, et al. Pathologic features of AIDS encephalopathy in children: evidence for LAV/HTLV-III infection of brain. Hum Pathol 1986; 17(3): 271-84.
246. [247] Ackermann C, Andronikou S, Laughton B, et al. White Matter Signal Abnormalities in Children With Suspected HIV-related Neurologic Disease on Early Combination Antiretroviral Therapy. The Pediatric infectious disease journal 2014; 33(8): e207-12.
247. [248] van Arnhem LA, Bunders MJ, Scherpbier HJ, et al. Neurologic abnormalities in HIV-1 infected children in the era of combination antiretroviral therapy. PLoS One 2013; 8(5): e64398.
248. [249] Prado PT, Escorsi-Rosset S, Cervi MC, Santos AC: Image evaluation of HIV encephalopathy: a multimodal approach using quantitative MR techniques. Neuroradiology 2011; 53(11): 899-908.
249. [250] Keller MA, Venkatraman TN, Thomas A, et al. Altered neurometabolite development in HIV-infected children: correlation with neuropsychological tests. Neurology 2004; 62(10): 1810-7.
250. [251] Mitchell W: Neurological and developmental effects of HIV and AIDS in children and adolescents. Ment Retard Dev Disabil Res Rev 2001; 7(3): 211-6.
251. [252] Solomons R, Slogrove A, Schoeman J, et al. Acute extrapyramidal dysfunction in two HIV-infected children. Journal of tropical pediatrics 2011; 57(3): 227-31.
252. [253] Giangaspero F, Scanabissi E, Baldacci MC, Betts CM: Massive neuronal destruction in human immunodeficiency virus (HIV) encephalitis. A clinico-pathological study of a pediatric case. Acta Neuropathol 1989; 78(6): 662-5.
253. [254] Epstein LG, Gendelman HE: Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann Neurol 1993; 33(5): 429-36.
254. [255] Da Cunha A, Mintz M, Eiden LE, Sharer LR: A neuronal and neuroanatomical correlate of HIV-1 encephalopathy relative to HIV-1 encephalitis in HIV-1 infected children. Journal of Neuropathology and Experimental Neurology 1997; 56(9): 974-87.
255. [256] Krajewski S, James HJ, Ross J, et al. Expression of pro-and antiapoptosis gene products in brains from paediatric patients with HIV-1 encephalitis. Neuropathology and Applied Neurobiology 1997; 23: 242-53.
256. [257] Canto-Nogues C, Sanchez-Ramon S, Alvarez S, Lacruz C, Munoz-Fernandez MA: HIV-1 infection of neurons might account for progressive HIV-1-associated encephalopathy in children. J Mol Neurosci 2005; 27(1): 79-89.
257. [258] Belman AL, Ultmann MH, Horoupian D, et al. Neurological complications in infants and children with acquired immune deficiency syndrome. Ann Neurol 1985; 18(5): 560-6.
258. [259] Castello E, Baroni N, Pallestrini E: Neurotological and auditory brain stem response findings in human immunodeficiency viruspositive patients without neurologic manifestations. Annals of Otolology, Rhinology & Laryngology 1998; 107: 1054-60.
259. [260] Goodin DS, Aminoff MJ, Chernoff DN, Hollander H: Long latency event-related potentials in patients infected with human immunodeficiency virus. Ann Neurol 1990; 27(4): 414-9.
260. [261] Vigliano P, Boffi P, Bonassi E, et al. Neurophysiologic exploration: a reliable tool in HIV-1 encephalopathy diagnosis in children. Panminerva medica 2000; 42(4): 267-72.
261. [262] Belman AL, Muenz LR, Marcus JC, et al. Neurologic status of human immunodeficiency virus 1-infected infants and their controls: a prospective study from birth to 2 years. Mothers and Infants Cohort Study. Pediatrics 1996; 98(6 Pt 1): 1109-18.
262. [263] Ultmann MH, Belman AL, Ruff HA, et al. Developmental abnormalities in infants and children with acquired immune deficiency syndrome (AIDS) and AIDS-related complex. Developmental medicine and child neurology 1985; 27(5): 563-71.
263. [264] Walker SY, Pierre RB, Christie CD, Chang SM: Neurocognitive function in HIV-positive children in a developing country. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2013; 17(10): e862-7.
264. [265] Lindsey JC, Malee KM, Brouwers P, Hughes MD: Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics 2007; 119(3): e681-93.
265. [266] Blanchette N, Smith ML, Fernandes-Penney A, King S, Read S: Cognitive and motor development in children with vertically transmitted HIV infection. Brain and cognition 2001; 46(1-2): 50-3.
266. [267] Koekkoek S, Eggermont L, De Sonneville L, et al. Effects of highly active antiretroviral therapy (HAART) on psychomotor performance in children with HIV disease. Journal of neurology 2006; 253(12): 1615-24.
267. [268] Watkins JM, Cool VA, Usner D, et al. Attention in HIV-infected children: results from the Hemophilia Growth and Development Study. Journal of the International Neuropsychological Society: JINS 2000; 6(4): 443-54.
268. [269] Nozyce ML, Lee SS, Wiznia A, et al. A behavioral and cognitive profile of clinically stable HIV-infected children. Pediatrics 2006; 117(3): 763-70.
269. [270] Foster SB, Lu M, Glaze DG, et al. Associations of cytokines, sleep patterns, and neurocognitive function in youth with HIV infection. Clinical immunology 2012; 144(1): 13-23.
270. [271] Langerak NG, du Toit J, Burger M, et al. Spastic diplegia in children with HIV encephalopathy: first description of gait and physical status. Developmental medicine and child neurology 2014; 56(7): 686-94.
271. [272] von Giesen HJ, Niehues T, Reumel J, et al. Delayed motor learning and psychomotor slowing in HIV-infected children. Neuropediatrics 2003; 34(4): 177-81.
272. [273] Blanchette N, Smith ML, King S, Fernandes-Penney A, Read S: Cognitive development in school-age children with vertically transmitted HIV infection. Dev Neuropsychol 2002; 21(3): 223-41.
273. [274] Becker JT, Sanders J, Madsen SK, et al. Subcortical brain atrophy persists even in HAART-regulated HIV disease. Brain imaging and behavior 2011; 5(2): 77-85.
274. [275] Coyle JT: Biochemical aspects of neurotransmission in the developing brain. Int Rev Neurobiol 1977; 20: 65-103.
275. [276] Lauder JM, Bloom FE: Ontogeny of monoamine neurons in the locus coeruleus, Raphe nuclei and substantia nigra of the rat. I. Cell differentiation. J Comp Neurol 1974; 155(4): 469-81.
276. [277] Royal W, Zhang L, Guo M, Jones O, Davis H, Bryant JL: Immune activation, viral gene product expression and neurotoxicity in the HIV-1 transgenic rat. J Neuroimmunol 2012; 247: 16-24.